Pembrolizumab Monotherapy Displays Efficacy in Rare Sarcomas
The PD-1 inhibitor pembrolizumab (Keytruda) displayed activity with a manageable safety profile in patients with certain rare and ultra-raresarcoma histotypes, according to findings from the phase 2 A
Updated on: November 07,2023
6

Pembrolizumab Monotherapy Displays Efficacy in Rare Sarcomas
The PD-1 inhibitor pembrolizumab (Keytruda) displayed activity with a manageable safety profile in patients with certain rare and ultra-raresarcoma histotypes, according to findings from the phase 2 A
Updated on:November 07,2023
6
